Heterotopic Ossification: Causes, Symptoms, and Treatment

Heterotopic ossification is the formation of true bone in places where bone does not belong, typically in soft tissues like muscle, tendons, or the tissue surrounding joints. It can show up as a barely noticeable deposit that never causes problems, or it can lock entire joints in place and severely limit movement. The condition arises in two broad contexts: acquired forms triggered by trauma, surgery, burns, or brain and spinal cord injuries, and rare genetic forms in which the body progressively converts muscle and connective tissue into bone over a lifetime.

What Causes Bone to Form in Soft Tissue

The core problem in every form of heterotopic ossification is that certain progenitor cells in soft tissue get pushed down an bone-forming pathway they were never supposed to follow. A signaling system called the bone morphogenetic protein (BMP) pathway, which normally guides skeletal development in the womb and bone repair after fractures, becomes active in the wrong place at the wrong time. When BMP signaling fires in muscle or connective tissue, local stem-like cells start behaving as though they have been told to build bone. They lay down cartilage first, then gradually replace it with mineralized bone, following almost the same sequence your skeleton used when it formed during fetal development.

Inflammation is the usual trigger for this misdirected signaling. After a severe injury, surgery, or burn, the body floods the damaged area with immune cells. Macrophages, which shift between pro-inflammatory and tissue-repair states, play a central role in steering the local environment toward bone formation by releasing signaling molecules that activate BMP and related pathways.¹ Neutrophils, the first immune cells to arrive at a wound, also contribute by activating BMP and TGF-β signals that push progenitor cells toward becoming bone-building cells.² In burn injuries specifically, the intense and prolonged inflammatory response, with surges in cytokines and chemokines, creates an environment especially hospitable to ectopic bone formation.³

Acquired Heterotopic Ossification

Most cases are acquired, meaning they develop after some identifiable insult to the body. The most common settings include major joint surgery (especially hip replacement), traumatic fractures, blast injuries, severe burns, and central nervous system injuries such as traumatic brain injury or spinal cord injury. Not everyone who undergoes hip surgery or sustains a fracture develops heterotopic bone, but certain situations carry much higher risk.

Combat and blast injuries are among the highest-risk scenarios. One study of combat casualties found an overall incidence of about 12%, with the vast majority of those cases linked to blast injuries.⁴ Among service members who sustained high-energy extremity wounds requiring amputation, rates climbed far higher, with one series reporting heterotopic ossification in roughly 65% of patients.⁵ The severity and type of tissue destruction appear to matter: open fractures treated with internal fixation, extensive soft-tissue damage, and prolonged wound healing all raise the likelihood.

Neurogenic heterotopic ossification, the kind that follows brain or spinal cord injury, has its own distinct features. It tends to form around large joints like the hip, knee, elbow, or shoulder on the paralyzed or affected side. The exact mechanism linking a brain injury to bone forming in a distant muscle remains incompletely understood. Circulating factors released by the injured nervous system, combined with local immobility and the inflammatory cascade, appear to converge to create the right conditions.⁶ Recent research has added another layer: infections, which are common after spinal cord injuries, can worsen the process. Molecules produced by bacteria and other pathogens activate pattern recognition receptors on immune cells and muscle progenitor cells, amplifying the inflammatory signals that drive bone formation.⁷

Genetic Forms and Fibrodysplasia Ossificans Progressiva

On the opposite end of the spectrum from a one-time post-surgical deposit sits fibrodysplasia ossificans progressiva (FOP), one of the rarest and most disabling genetic conditions known. People with FOP are born with a mutation that keeps BMP signaling permanently overactive. Even minor bumps, viral illnesses, or intramuscular injections can trigger flare-ups in which muscle and connective tissue are progressively replaced by bone, eventually forming a second skeleton that locks joints in place. The disease is devastating: over time it restricts breathing, eating, and virtually all voluntary movement.⁸

Nearly all classic FOP cases trace to a single point mutation in the ACVR1 gene, which encodes a BMP receptor. The mutation swaps one amino acid for another at position 206, turning the receptor into one that is mildly active even when it should be off and overly sensitive when it is turned on.⁹ Later work showed that the mutated receptor gains an abnormal ability to respond to a signaling molecule called activin A, which normally does not trigger bone formation through this receptor. That abnormal responsiveness appears to be a key driver of the disease.⁸ The clinical picture of FOP, where lesions range from small foci to massive whole-body deposits, illustrates the full spectrum of what heterotopic ossification can look like.¹⁰

Quality of life in FOP deteriorates progressively as more joints become immobilized. Surveys of patients confirm what anyone would expect: the relentless loss of physical ability causes significant psychological and social burden alongside the physical disability.¹¹ Surgical removal of the misplaced bone is not an option in FOP because the surgery itself triggers a new round of bone formation.

How It Feels and How It Is Found

Heterotopic ossification is often silent. Many people who develop small deposits after hip surgery never notice them; the bone shows up incidentally on an X-ray taken for another reason. When it does cause symptoms, the hallmarks are swelling, warmth, and reduced range of motion around a joint. The area may feel firm or hard to the touch, and moving the joint becomes increasingly difficult as the bone matures. Pain is common early on, during the inflammatory phase, but may diminish once the bone fully forms and the inflammation subsides.

Catching it early matters because prevention strategies work best before the bone has fully hardened. Standard X-rays often lag behind: it takes an average of about 23 days after symptoms appear for plain films to show visible bone deposits. Ultrasound can pick up changes much sooner, detecting abnormal tissue within days of the first symptoms, and is now considered a strong option for early screening, especially in high-risk populations like spinal cord injury patients.¹² Bone scans using a radioactive tracer were once the go-to for early detection, but their limited ability to distinguish heterotopic ossification from other inflammatory conditions has made ultrasound an increasingly preferred alternative.

Researchers are also investigating blood-based biomarkers that could flag the process before imaging picks it up. A panel of proteins associated with bone turnover, including osteocalcin, osteomodulin, and a form of collagen, has shown promise in distinguishing patients who are developing heterotopic bone from those with normal wound healing.¹³ A reliable blood test would be especially valuable for burn and blast-injury patients, in whom early intervention could prevent months of additional disability.

Prevention With Medications and Radiation

Because established heterotopic bone is difficult to reverse without surgery, a great deal of clinical effort goes into preventing it in the first place, particularly around high-risk surgeries like hip replacement and in patients with spinal cord injuries.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used preventive measure. Indomethacin, one of the oldest and most potent NSAIDs, has the strongest evidence base. A systematic review and meta-analysis of randomized trials found that indomethacin significantly reduced the occurrence of lower-grade heterotopic ossification around the hip compared to no treatment, though it did not significantly prevent the more severe grades.¹⁴ When indomethacin was compared head-to-head with meloxicam, another NSAID, after hip replacement, the indomethacin group developed heterotopic bone in about 10% of cases versus 25% for meloxicam, a statistically meaningful difference.¹⁵ The downside of indomethacin is its side-effect profile: stomach irritation, kidney effects, and potential interference with bone healing at the surgical site itself are real concerns, which is why the treatment course is typically kept short.

For spinal cord injury patients, a systematic review found that NSAIDs showed the greatest preventive benefit when started early after injury, while bisphosphonates had the strongest supportive evidence once heterotopic bone had already begun to form.¹⁶

Radiation therapy is the other major preventive tool, used most often around hip surgery. A single low dose of radiation delivered to the surgical site, typically around 700 centigray, is the most common protocol. A systematic review found no significant difference in outcomes between giving radiation before or after surgery, or between different dose levels, suggesting that the approach is relatively forgiving in terms of timing and dose.¹⁷ Radiation works by killing the rapidly dividing progenitor cells that would otherwise be recruited into bone formation. It is generally well tolerated as a single fraction, though there are theoretical concerns about long-term effects in younger patients.

Surgical Removal of Established Bone

When heterotopic bone has matured and is restricting joint movement or causing persistent pain, surgical excision is often the only way to restore function. The surgery is straightforward in concept: cut out the misplaced bone, free the joint, and then try to prevent it from coming back. In practice, it gets complicated.

Timing matters. In combat-related amputees, excisions performed within six months of the original injury were about four times more likely to require a second surgery for symptomatic recurrence compared to those done later. Partial removal also carried a higher risk of recurrence than complete excision: roughly 27% of partial excisions showed radiographic recurrence compared to about 7% of complete ones.¹⁸ The traditional teaching was to wait until the bone had fully matured, sometimes a year or more, before operating. For neurogenic heterotopic ossification following brain injury, a systematic review concluded that delayed surgery did not actually reduce recurrence, and excision could proceed once the patient’s other medical issues were controlled and the bone was solid enough to remove cleanly.¹⁹

After excision, prophylaxis against regrowth is standard. Most surgeons use either indomethacin, perioperative radiation, or both. In severe cases after hip replacement, a systematic review of excision for the highest grades of heterotopic ossification found that recurrence was uncommon when prophylaxis was used, occurring in only two patients across the included studies.²⁰

Bisphosphonates for Active Disease

Bisphosphonates, the same class of drugs used to treat osteoporosis, have a somewhat different role here. They work by interfering with bone remodeling, potentially slowing the maturation and mineralization of heterotopic bone that is already forming. They are not as well established for prevention as NSAIDs, but they come into play once heterotopic ossification is underway, particularly in spinal cord injury patients. A recent systematic review confirmed that bisphosphonates appear to reduce the extent of bone formation in this population, though the evidence is not yet strong enough to define the ideal drug, dose, or duration.²¹

Case reports have also documented their use in sports-related muscle ossification. In one published case, a football player who developed bone within his quadriceps muscle after a direct blow was treated with intravenous pamidronate, a bisphosphonate. The treatment was associated with clinical and imaging improvement and a drop in bone-turnover markers in the urine.²² That is a single case, not proof of broad effectiveness, but it illustrates that clinicians sometimes reach for bisphosphonates when surgery is not immediately appropriate or desirable.

Targeted Therapies for FOP

For patients with fibrodysplasia ossificans progressiva, the standard acquired-HO toolkit is largely useless. NSAIDs do not stop flare-ups, radiation cannot be applied to the whole body, and surgery is off the table because it provokes more bone growth. The disease demands therapies that target its specific molecular cause.

Palovarotene, a drug that activates the retinoic acid receptor gamma pathway, became the first compound approved by the FDA to treat heterotopic ossification in FOP patients.²³ The drug works by blocking the cartilage-formation step that precedes bone formation, essentially interrupting the process before the misplaced bone can mineralize. In mouse models carrying the human FOP mutation, palovarotene prevented spontaneous heterotopic bone formation, maintained growth plate function, and preserved limb mobility.²⁴

Human trial data have been more sobering. Through 48 months of the phase 3 MOVE trial, palovarotene-treated patients showed about 46% less new heterotopic bone volume compared to untreated patients, but the difference narrowly missed statistical significance.²⁵ That gap between “looks like it helps” and “we can prove it helps” reflects the enormous challenge of running clinical trials in a disease so rare that enrolling large numbers of patients is practically impossible. The drug received approval based on the totality of available evidence, including its mechanism, animal data, and the limited human data, reflecting a regulatory judgment that for a disease this devastating, the bar need not be the same as for common conditions.

Other approaches are still in the pipeline. Gene therapy strategies using viral vectors to either silence the mutated copy of ACVR1 or replace it with a normal version have shown proof-of-concept success in laboratory models.²⁶ These approaches are years from clinical use, but they represent the possibility of addressing the root genetic defect rather than managing its downstream consequences.

When Athletes and Weekend Warriors Get It

Heterotopic ossification is not just a concern for surgical patients and trauma victims. It shows up in the sports medicine world too, where it goes by the older name myositis ossificans. A hard hit to the thigh during a football tackle, a direct blow to the arm in a contact sport, or even a severe muscle strain can, in some people, lead to a lump of bone forming within the injured muscle over the following weeks. The quadriceps is the most common site, followed by the upper arm.

The initial presentation looks a lot like a deep bruise that is not getting better on schedule: persistent swelling, pain, and a palpable firm mass. Imaging confirms the diagnosis, usually with ultrasound or CT. Most cases in athletes are self-limiting. The bone deposit matures over several months and often shrinks or stops causing problems on its own, especially if the athlete avoids re-injuring the area. Aggressive early stretching or massage of a suspected deep muscle injury is widely discouraged because it can worsen the inflammatory response and promote bone formation. The standard approach is rest, gentle range-of-motion exercises only as tolerated, and patience. If the mass continues to limit function after it has fully matured, surgical excision becomes an option.

The Role of Progenitor Cells

One of the more active areas of research concerns which cells in the body are actually responsible for building misplaced bone. The answer turns out to be less straightforward than early models assumed. Studies using genetic lineage tracing in mice have identified a population of stem-like cells marked by a protein called Gli1, which normally reside near blood vessels in various tissues, as major contributors to the cartilage and bone that form during heterotopic ossification.²⁷ Other work has shown that the mutant BMP receptor in FOP accelerates the rate at which progenitor cells commit to becoming cartilage, essentially fast-tracking the first stage of bone formation.²⁸

Understanding which cells participate is not just academic. If the cells that build misplaced bone can be reliably identified by their surface markers, it becomes possible to design therapies that target those cells specifically while leaving normal bone repair and other stem cell functions intact. That specificity is the missing piece in current treatments: NSAIDs and radiation work by broadly suppressing inflammation or killing dividing cells, which is effective but blunt. A therapy that could tell wayward progenitor cells to stand down without affecting the rest of the body’s healing machinery would change the game for both acquired and genetic forms of the condition.